Cancer is one of the diseases for which RNA interference is a potential therapeutic approach. Genes involved in the promotion or maintenance of tumor growth are obvious targets for RNAi. RNAi is also considered an attractive additional approach to conventional chemotherapy for cancer treatment. Moreover, siRNAs have shown a high specificity for their molecular target mRNAs as they can selectively inhibit cancer-promoting genes that differ by a point mutation. Loss of heterozygosity (LOH) reduces genes to hemizygosity in cancer cells and presents an absolute difference between normal and cancer cells. The regions of LOH are usually much larger than the tumor suppressor gene, which is lost, and has been shown to contain genes that are essential for cell survival. Single-nucleotide polymorphisms (SNPs) are the most common type of genetic variation in man. SNPs in essential genes that are frequently affected by LOH can be used as a target for a therapy against cancer cells with LOH. We have designed siRNAs against the gene of the large subunit of RNA polymerase II (POLR2A), a gene located in close proximity to the tumor suppressor gene p53, which frequently shows LOH in cancer cells. It is shown in vitro that siRNA can selectively inhibit POLR2A expression dependent on its genotype. Furthermore, cancer cell proliferation and tumor growth inhibition in nude mice was genotype dependent. We conclude that siRNA can be used for genotype-specific inhibition of tumor growth targeting an SNP in POLR2A in vivo.
Introduction
RNA interference (RNAi) [1] [2] [3] was first discovered in Caenorhabditis elegans as a potent gene-silencing mechanism. 4 The inhibition of specific gene expression by means of RNAi has also been achieved in mammalian cells by directly introducing short dsRNA (siRNA) into cells, which avoids a response evoked by long dsRNA. 5 Cancer is clearly an important potential target for RNAi-based therapies. 6 Target molecules usually represent genes that have been shown previously to be relevant or rate limiting for tumor growth, including growth factors and receptors as well as antiapoptotic or downstream signal transduction proteins in cancer cells. 7 Often these targeted molecules are not unique for cancer cells thereby limiting the therapeutic window or these molecules appear to be redundant leading to resistance. Therefore, targeting of molecules that are unique in cancer cells may lead to more specific therapeutic interventions.
One of the differences between cancer cells and normal cells is that cancer cells have lost large segments of DNA. The loss of large chromosomal regions, or even whole chromosomes, is an early event in the clonal evolution of cancers. Loss of heterozygosity (LOH) can involve 420% of the total genome in certain cancers. 8 This irreversible difference between normal and tumor cells forms the basis of an approach for anticancer drug development, called allele-specific inhibition (ASI) 9 (reviewed in 10 ). We have previously identified a large number of single-nucleotide polymorphisms (SNPs) in genes that are essential for cell survival and are localized in chromosomal regions often involved in LOH in various cancer types. 11 Inhibition of the hemizygous essential gene left in the cancer cells will lead to specific cancer cell death. The heterozygous normal cells will loose maximally half of the expression of the gene by this approach and cell survival is not affected. Classic antisense approaches have shown proof of principle of ASI in vitro 9, 11 and in vivo. 12 However, antisense-based approaches have some specific limitations that can likely be overcome by the use of siRNA.
Over the past few years, several studies have reported the selective silencing of mutant alleles resulting from single-nucleotide point mutations by RNAi. 2, [13] [14] [15] [16] [17] In line with that, systematic analysis of a single-nucleotidemismatched target showed that when the character and the position of the mismatch is carefully considered, a single mismatch can render an siRNA ineffective. 18, 19 Therefore, the sequence specificity and the high success rate of finding a potent siRNA made it an attractive molecule for ASI. In our approach we used siRNA to target an essential gene (POLR2A) that is present in only one copy in the cancer cell but present as a heterozygous gene in normal cells. Heterozygosity due to a SNP in POLR2A protects normal cells whereas hemizygosity for POLR2A it is lethal for cancer cells.
In this study we show in vitro that siRNAs can discriminate between two allelic forms of POLR2A that differ by a single nucleotide in the target sequence. Systemic delivery of unformulated siRNA resulted in genotype-specific growth inhibition in vivo.
Materials and methods

siRNA synthesis
Six siRNA duplexes (Proligo, Paris, France) targeted to the POLR2A C/T SNP at position 2673 relative to the start codon were designed (Table 1; Figure 1) . A siRNA targeting eGFP (siGFP; Table 1 ) was purchased from MedProbe (Lund, Sweden) and was used as a control for in vivo experiments. In all siRNAs, a two DNA nucleotide overhang was added at the 3 0 end to stabilize the duplex. Sense and antisense strands were chemically synthesized and obtained annealed.
Cell lines
The pancreatic cancer cell line MiaPaca II (T genotype) and the prostate cancer cell line 15PC3 (C genotype) were maintained at 37 1C and 5% CO 2 by serial passage in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin.
Transfections
Transfections were performed in six-well culture plates with Lipofectamine 2000 as transfection agent. For transfections the siRNA concentrations ranged between 5 and 100 nM. Total RNA was isolated 24 h posttransfection. Protein samples were 72 h posttransfection.
Northern blots
Cells were harvested in Trizol (Gibco, Breda, The Netherlands) after removing the growth medium 24 h posttransfection. The RNA isolation was according to the manufacturer's procedure. RNA was denatured using glyoxal and separated on 1% agarose gels, following standard protocols. RNA was subsequently transferred to Hybond-N þ membrane (Amersham, Roosendoal, The Netherlands) in 20 Â SSC. Following transfer the RNA was UV crosslinked and the membrane was baked for 4 h at 80 1C. To detect POLR2A and 28S mRNA, we used the probes previously described. 20 Hybridizations and posthybridization washes were according to Church and Gilbert. 21 POLR2A mRNA levels were quantified using Aida software version 3.44 (Raytest, Tilburg, The Netherlands) and normalized to the levels of 28S mRNA.
Western blots
Cell extracts were prepared in lysis buffer (PBS; 1% Triton X-100, 0.01% sodium azide), were subjected to SDS-polycrylamide gel (6%) electrophoresis (SDS-PAGE), and the resolved proteins were transferred electrophoretically to polyvinylidene fluoride (PVDF) membranes (Invitrogen, Breda, The Netherlands). POL-R2A was detected with a mouse-anti-POLR2A monoclonal antibody (clone 8WG16; RDI). Elongation factor2a (rabbit-anti-eEF2a; Cell Signaling, Damvers, MA) was used as loading control. Chemiluminescent detection was performed on a LAS3000 (Fuji, Tokyo, Japan) in accordance with the manufacturer's instructions. POL-R2A protein levels were quantified using Aida software Data points were fitted with GraphPad Prism using linear regression in order to calculate the tumor growth rates (GraphPad Prism Software Inc., San Diego, CA). Growth rates of tumors in siRNA-treated animals were normalized to the growth rates of tumors in saline treated animals. Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) levels in serum were determined using standard diagnostic procedures with the appropriate kits (Roche Diagnostics, Mannheim, Germany). For each treatment, five mice per group were used. All animal experiments were conducted under the institutional guidelines and according to the law; they were sanctioned by the animal ethics committee.
Results
In vitro genotype-specific inhibition of POLR2A mRNA and decreased POLR2A protein levels is dependent on the relative position of the SNP To test the sequence specificity of siRNA we used the human cancer lines MiaPaca II and 15PC3. These cell lines differ in sequence of POLR2A at position c.2673. As POLR2A encodes an essential gene in mammalian cells inhibition of gene expression would result in diminished cell growth. POLR2A mRNA levels, protein levels and growth inhibition were used as readout for sequence specificity. In MiaPaca II cells (T genotype), POLR2A mRNA was downregulated by si10T. Its allelic variant si10C did not show downregulation of POLR2A mRNA. Introduction of one mismatch at ninth position of the siRNA targeting the T genotype (si10TM9) completely abrogated its ability to downregulate POLR2A. POLR2A expression in MiaPaca II cells was also not affected by a siRNA targeting the C genotype with an additional mismatch at ninth position (si10CM9), having two mismatches with this genotype (Figure 2a) . We observed sequence-specific POLR2A mRNA knockdown with siRNA at concentration as high as 100 nM (data not shown). Shifting the position of the siRNA so that the SNP was opposite to the seventh position in the siRNA (si7T) resulted in loss of sequence specificity. Both si7T and si7C downregulated POLR2A independent of the c.2673 genotype (Figure 2a ). This confirms previous findings that showed that ASI is dependent on the relative position of the mismatch.
Transfection of the same set of siRNAs into 15PC3 cells (C genotype) showed similar results. si10C effectively downregulated POLR2A mRNA (Figure 2b) . The siRNAs si10T, si10CM9 and si10TM9 were not effective, not even at a concentration of 100 nM, whereas si7C and si7T were both effective in POLR2A mRNA knockdown at all the concentrations used (Figure 2b) . These results show that in in vitro experiments siRNA can discriminate between two genotypes that differ only in one nucleotide. Discrimination was observed over a range of siRNA concentrations up to 20 times the effective concentration of 5 nM. However, discrimination was dependent on the relative position of the SNP. POLR2A protein levels in MiaPaca II and 15PC3 cells ( Figure 3 ) correlated with POLR2A mRNA levels. Effect of siRNAs targeting POLR2A on cell growth As POLR2A is an essential component of the transcriptional machinery, downregulation is cytotoxic. Therefore we can easily study whether allele-specific siRNA can mediate specific target knockdown while leaving its allelic variant that differs only for one nucleotide, unaffected.
To test the siRNA specificity in a toxicity assay, MiaPaca II and 15PC3 cells were transfected with the same siRNAs against POLR2A and cell survival was observed for 4 days. At 1-day posttranfection there were no obvious differences between the transfections in either cell line, indicating similar seeding and recovery of the cells after plating them. At 5 days posttransfection, MiaPaca II cells (T-genotype) that were transfected with siRNAs that had no effect on POLR2A expression in this cell line (si10C, si10CM9, si10TM9) or mock transfection had grown to confluence (Figure 4 ). Transfection with siRNAs that knocked down POLR2A in this cell line (si10T, si7C and si7T) resulted in cell death and subsequent detachment from their surface ( Figure 4 ). Likewise, 15PC3 cells (C genotype) transfected with siRNAs that had no effect on POLR2A expression in this cell line (si10T, si10CM9, si10TM9) grew at similar rates as mock transfected cells and all grew confluent in 5 days (Figure 4 ). siRNAs that effectively lowered POLR2A mRNA and protein in 15PC3 cells (si10C, si7C and si7T) also resulted in cell death and detachment from the surface (Figure 4 ). This demonstrates that the fully matched siRNAs si10C and si10T targeting POLR2A were toxic but more importantly, for siRNAs carrying a single mismatch at position 9 or 10, no toxicity was observed in this time frame. Therefore, si10C and si10T are potential candidates for genotype-specific drugs.
Genotype-specific tumor growth inhibition
Since the final goal of our approach is the development of an allele-specific cancer drug we tested whether siRNA directed against POLR2A could inhibit growth of tumor xenografts dependent on their genotype. Growth of MiaPaca II xenografts was inhibited in mice treated with systemically administered si10C, si10T and si10TM9. In contrast to the in vitro experiments, a single mismatch of a siRNA with its target mRNA was toxic in vivo ( Figure 5a ). Animals treated with siRNA with 2 mismatches (si10CM9) and siRNA targeting eGFP showed similar growth rates of the MiaPaca II xenograft as in the saline treated animals ( Figure 5a ). Introduction of a second mismatch with the T-genotype was necessary to obtain genotype-specific growth inhibition. Likewise, in 15PC3 xenografts tumor growth was inhibited by si10C, si10T and si10CM9 (Figure 5b ). No growth inhibition was observed with si10TM9 which has two mismatches with the C-genotype and siRNA targeting eGFP (Figure 5b ). This demonstrates that also in 15PC3 xenografts two mismatches were needed to prevent tumor growth inhibition and again a single mismatch is not sufficient to render a siRNA ineffective in vivo. Therefore, si10CM9 and si10TM9 showed ASI of tumor growth (Figures 5a and b) . Serum ASAT and ALAT levels, as determined after killing of the animals, did not differ significantly between the treatment groups indicating that POLR2A   eEF2α   si10C  si7C  si7T  Mock  si10T  si10CM9  si10TM9  si10C  si7C  si7T  Mock  si10T si10CM9 si10TM9 Allele-specific inhibition of tumor growth ORF Mook et al there was no liver toxicity due to administration of the siRNAs (data not shown).
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Discussion
Allele specific inhibition is a promising approach for the treatment of various diseases including cancer. 10, 13, 14, 25 Proof of principle for ASI has been shown previously using antisense oligonucleotides (ODNs) 9, 20 and siR-NA 16, 17 in vitro. In vivo, tumor growth could be inhibited allele specifically using antisense oligonucleotides however only with a very small therapeutic window.
12 ASI mediated by intravenously administered chemically synthesized siRNA in vivo has not been shown before.
Here we show that ASI by siRNA can be applied both in vitro and in vivo. We show in two genotypically different cells lines that proper base pairing at the ninth and tenth position of the antisense strand of siRNA and its target RNA is important for its function because a mismatch at these positions rendered siRNA directed against POLR2A inactive. This is in line with the observation that RNAi is lost upon introduction of central mismatches (positions 9-11). [13] [14] [15] [16] [17] [18] [25] [26] [27] The catalytic site is at that region and apparently loss of proper base pairing at those specific positions results in loss of RNAi. This was strengthened by the finding that the same mismatches (C:A and G:U) at the seventh position in the AS strand were tolerated.
However, it has been shown recently that besides the position, the nature of the mismatch is also involved in target recognition. 18, 19 Unfortunately, these rules do not apply the same to different targets. For example, a C:A mismatch at the tenth position did not affect gene silencing, 26 resulted in target knockdown of only approximately 25% 18 or as shown in our study was not tolerated at all. If this also applies for a G:U mismatch at the tenth position was not investigated in this particular studies.
In our study, the introduction of a mismatch at the ninth position resulted in a G:A mismatch. In general, bulky purine-purine mismatches, A:A and G:A, are much less tolerated and therefore render an siRNA inactive. 18 Specifically, mutated K-RAS V12 was discriminated from its wild-type variant based on a A:G mismatach at position 9.
2 This is in agreement with our study that showed loss of RNAi upon the introduction of a G:A mismatch at the ninth position. There are a limited number of exceptions to the central region; C:U mismatch at the sixteenth position, 28 G:G mismatch at the seventeenth position for CEACAM6 siRNA 22 and a C:T mismatch at the seventh position 29 and studied systematically. 18, 19 We next tested if siRNA could inhibit growth of xenografted tumors in nude mice in a genotype (allele)-specific manner. It has recently been shown by us 23 and others that low dosages of unmodified siRNA can mediate RNAi in vivo. 22, 30, 31 We show siRNA mediated genotype (allele)-specific inhibition of tumor growth. However, siRNAs carrying one mismatch, either at the ninth or tenth position, with its target retained activity in vivo.
Combination of these two mismatches was necessary to render the siRNA ineffective and achieve ASI. It is unclear why in vitro selected genotype-specific siRNA lost its specificity in vivo but the observed effect in vivo must be sequence dependent as siRNA with two mismatches targeting POLR2A and siRNA targeting GFP did not inhibit tumor growth whereas fully matched or one mismatched siRNAs targeting POLR2A did inhibit tumor growth.
Mouse and human POLR2A are highly homologous but differ at two bases from the human sequence in the targeted region of the mRNA. Thus, depending of the human genotype, two or three mismatches are present. These mismatches are sufficient prevent POLR2A knockdown in mouse tissues. Xenografts are composed of human cancer cells and mouse stromal cells. Stromal POLR2A is not inhibited and cannot be discriminated from human POLR2A on western or northern blots. It is therefore not possible to determine the human POLR2A levels in xenografts reliably.
In conclusion, siRNA-mediated ASI is a potential therapeutic application to inhibit tumor growth in vivo.
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